ClinicalTrials.gg
CompletedNCT01371357Updated Dec 20, 2011

The Effects of 8-week Choline, Betaine, and Folic Acid Supplementation on Plasma Homocysteine Concentration During Guanidinoacetic Acid Loading in Young Healthy Volunteers

A Phase 3 interventional study of TEST 1 and TEST 2 in Hyperhomocysteinemia, sponsored by Center for Health, Exercise and Sport Sciences, Serbia. Completed at 1 site in Serbia. Open to participants aged 18 Years to 30 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-12-20.

Sponsored by Center for Health, Exercise and Sport Sciences, Serbia · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 30 Years
Sex
All
01

Study summary

A methyl-group acceptor such as guanidinoacetic acid (GAA) could induce hyperhomocysteinemia with the effects of GAA expected to be dose-dependent. Due to the fact that hyperhomocysteinemia is thought to be an independent risk factor for cardiovascular and neurodegenerative diseases, different dietary agents were used in the past for the treatment of elevated total plasma homocysteine (T-HCy), e. g. betaine, choline (betaine precursor) or folic acid. In the context of GAA loading the question arises whether intake of betaine, choline (betaine precursor) or folic acid during GAA loading could affect plasma T-HCy in healthy humans. Forty healthy physically active men and women aged 20 to 30 years will take part in this GAA-controlled, double-blind and parallel-group intervention study. Subjects will be allocated to four randomly assigned trials, with treatment lasting for 8 weeks and washout period of 28 days. The 4 test treatment-groups will include TEST1 (GAA only), TEST2 (GAA, choline, B6, B12 and folic acid), TEST3 (GAA, betaine, B6, B12 and folic acid) and TEST4 (GAA, B6, B12 and folic acid). Plasma T-HCy will be the primary outcome measure assessed every second week throughout the study. Plasma B-vitamins and blood and urine metabolites (GAA, creatine, methionine, arginine) will be secondary outcome measures along with adverse-effects indicators assessed every second week throughout the study. Selected body composition indicators will be obtained at 0, 2, 8 and 12 weeks throughout the study to monitor the effects of experimental treatments on body hydration and protein synthesis. This research will test the hypothesis that a combination of GAA with homocysteine lowering nutrients attenuates the elevation of T-hcy, and will further display the size-effect of each additive used.

02

Conditions studied

  • Hyperhomocysteinemia

Browse trials for

Keywords

  • Remethylation
  • Human Subjects
  • Clinical Trial
  • B-vitamin
  • Creatine
03

In context

Hyperhomocysteinemia

34 studies on the registry are indexed under Hyperhomocysteinemia; 4 are open to participants now.

This study's enrollment of 40 is below the median of 84 across 21 interventional studies indexed under Hyperhomocysteinemia.

Browse Hyperhomocysteinemia studies →

Lead sponsor

Center for Health, Exercise and Sport Sciences, Serbia is the lead sponsor of 7 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 30 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • healthy male and non-pregnant females
  • moderately physically active
  • aged 20 to 30 years
  • not currently taking any dietary supplement for the past 2 months

Exclusion criteria

Exclusion Criteria:

  • total plasma homocysteine above 15.5 µmol/L
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    TEST1

    2.4 g/day of guanidinoacetic acid

    Drug: TEST 1

  • Experimental
    TEST 2

    2.4 g/day of guanidinoacetic acid + 3.0 g/day of choline dihydrogen citrate + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid

    Drug: TEST 2

  • Experimental
    TEST 3

    2.4 g/day of guanidinoacetic acid + 1.6 g/day of betaine HCl + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid

    Drug: TEST 3

  • Experimental
    TEST 4

    2.4 g/day of guanidinoacetic acid + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid

    Drug: TEST 4

Interventions

  • DrugTEST 1

    2.4 g/day of guanidinoacetic acid

  • DrugTEST 2

    2.4 g/day of guanidinoacetic acid + 3.0 g/day of choline dihydrogencitrate + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid

  • DrugTEST 3

    2.4 g/day of guanidinoacetic acid + 1.6 g/day of betaine HCl + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid

  • DrugTEST 4

    2.4 g/day of guanidinoacetic acid + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid

06

What researchers measure

Primary outcomes

  1. Total plasma homocysteine

    Time frame: 3 months

Secondary outcomes

  1. Serum creatine

    Time frame: 3 months

07

Study locations

1 site
  • Center for Health, Exercise and Sport Sciences
    Belgrade, 11000, Serbia
08

References and documents

Publications

  • Olthof MR, Brink EJ, Katan MB, Verhoef P. Choline supplemented as phosphatidylcholine decreases fasting and postmethionine-loading plasma homocysteine concentrations in healthy men. Am J Clin Nutr. 2005 Jul;82(1):111-7. doi: 10.1093/ajcn.82.1.111. PubMed 16002808 ↗
  • Setoue M, Ohuchi S, Morita T, Sugiyama K. Hyperhomocysteinemia induced by guanidinoacetic acid is effectively suppressed by choline and betaine in rats. Biosci Biotechnol Biochem. 2008 Jul;72(7):1696-703. doi: 10.1271/bbb.70791. Epub 2008 Jul 7. PubMed 18603787 ↗
  • Verhoef P, de Groot LC. Dietary determinants of plasma homocysteine concentrations. Semin Vasc Med. 2005 May;5(2):110-23. doi: 10.1055/s-2005-872397. PubMed 16047264 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 20, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01371357
Lead sponsor
Center for Health, Exercise and Sport Sciences, Serbia
Responsible party
Assoc. Prof. Sergej M. Ostojic, MD, PhD (Head of Exercise Physiology Lab, Center for Health, Exercise and Sport Sciences, Serbia) — Principal investigator
First posted
Jun 10, 2011
Start date
May 2011
Primary completion
Dec 2011
Completion
Dec 2011
Last update
Dec 20, 2011

Study contacts

Sergej M Ostojic, MD, PhD
principal investigator · Center for Health, Exercise and Sport Sciences

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion